Sylvain Meloche, Ph.D.

Awards & Honours

  • Biotechnology of Tomorrow Award, Genesis Awards, 2009
  • Canada Research Chair in Cellular Signalling, 2004–
  • Scientist, Medical Research Council of Canada, 1998-2003
  • Scholar, Medical Research Council of Canada, 1992-1997
  • Joe Doupe Young Investigator Award, Canadian Society for Clinical Investigation, 1995


  • Postdoctoral training with Jacques Pouysségur, Université de Nice, France, 1990-1992
  • Postdoctoral training with Rafick-Pierre Sékaly, Institut de recherches cliniques de Montréal, 1988-1990
  • Ph.D. in Molecular Pharmacology with Huy Ong and André De Léan, Université de Montréal, 1988
  • M.Sc. in Pharmaceutical Sciences, Université de Montréal, 1984

Research Support

  • Canadian Cancer Society Research Institute
  • Canadian Institutes of Health Research
  • Cancer Research Society
  • Génome Québec
  • Natural Sciences and Engineering Research Council of Canada

After his doctoral studies in molecular pharmacology at Université de Montréal, Sylvain Meloche did his postdoctoral training in immunology at the Institut de recherches cliniques de Montréal, and in biochemistry at the Université de Nice, in France. Throughout this period, he was supported by the Medical Research Council of Canada and won awards from some of Canada’s most important granting agencies in recognition of the quality of his work.

He started his career as an independent investigator in 1992 when he set up his lab at the Research Center of the Centre hospitalier de l’Université de Montréal.

He is one of the founding members of IRIC that he joined in 2003. The team of Sylvain Meloche has made several major contributions to the fields of cell signaling and cell proliferation control over the years.  Among his most significant achievements is the demonstration of the key role of the MAP kinases ERK1/ERK2 in cell proliferation. This work had a major impact on the understanding of the biological functions of this major signaling pathway, which is now targeted by several targeted cancer therapies. His lab also pioneered the study of the structure, regulation and functions of the atypical MAP kinases ERK3 and ERK4. Notably, they have created several genetically-engineered mouse models that are deficient in these various MAP kinase enzymes.

Sylvain Meloche also made important discoveries about novel regulatory mechanisms of the cell cycle inhibitors p27 and p21, which play important tumor suppressor activities.

Follow IRIC

Logo UdeM